Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data related to its latent virus portfolio regarding cytomegalovirus (CMV), at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Barcelona, Spain, from April 27-30, 2024.

Moderna will be presenting nine presentations at the ESCMID Global Congress, including two late-breaker oral presentations, two oral presentations, and five poster presentations:

COVID-19

• P0422: The mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients
  Poster Session, Saturday, April 27 – 12:00 (Poster area)
  Presenter: Bethany Girard
• P0553: Comparative effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: a systematic literature review and meta-analysis using the GRADE framework
  Poster Session, Saturday, April 27 – 12:00 (Poster area)
  Presenter: Ekkehard Beck
• OS104: Safety and immunogenicity of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine
  1-hour Oral Session, Sunday, April 28 – 11:00 (Hall O)
  Presenter: Spyros Chalkias
• OS262: Demographic diversity of participants in infectious disease vaccine clinical trial
  1-hour Oral Session, Tuesday, April 30 – 11:00 (Hall J)
  Presenter: Jameka Hill

Influenza

• P0109: Next-generation mRNA-based seasonal influenza vaccines including additional A/H3N2 strains: Phase1/2 trial findings in adults aged 50 to 75 years
  Poster Session, Saturday, April 27 – 12:00 (Poster area)
  Presenter: Denise Hsu
• P0088: Consumer preferences for features of influenza vaccines in the United Kingdom: results from a discrete-choice experiment study
  Poster Session, Saturday, April 27 – 12:00 (Poster area)
  Presenter: Deborah Rudin
• OS235: Safety and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults
  1-hour Oral Session, Monday, April 29 – 17:30 (Hall I)
  Presenter: Mieke Soens

Respiratory Syncytial Virus (RSV)

• OS102: Coadministration of a respiratory syncytial virus vaccine (mRNA-1345) with an influenza or SARS-CoV-2 vaccine in older adults
  1-hour Oral Session, Monday, April 29 – 11:00 (Hall C)
  Presenter: Jaya Goswami

Cytomegalovirus (CMV)

• P0180: Potential relationship between cytomegalovirus and immunosenescence: evidence from observational studies
  Poster Session, Saturday, April 27 – 12:00 (Poster area)
  Presenter: John Diaz-Decaro

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for Moderna’s vaccine candidates to alleviate disease outcomes, the potential for co-administration of mRNA vaccines, and and the potential safety and immunogenicity of mRNA-1283. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Luke Mircea Willats
Senior Director, Corporate Communications
Luke.Mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on accesswire.com